PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
41.00%
Gross profit growth under 50% of AGEN's 385.58%. Michael Burry would be concerned about a severe competitive disadvantage.
27.93%
EBIT growth below 50% of AGEN's 90.41%. Michael Burry would suspect deeper competitive or cost structure issues.
27.93%
Operating income growth under 50% of AGEN's 90.59%. Michael Burry would be concerned about deeper cost or sales issues.
29.77%
Net income growth 1.25-1.5x AGEN's 25.58%. Bruce Berkowitz would see if strategic cost cutting or product mix explains this difference.
30.61%
EPS growth 1.25-1.5x AGEN's 24.62%. Bruce Berkowitz would check if strategic initiatives like cost cutting or better capital management explain the difference.
30.61%
Diluted EPS growth 1.25-1.5x AGEN's 24.62%. Bruce Berkowitz would verify if strategic moves (e.g., targeted acquisitions, cost cuts) explain the edge.
2.13%
Slight or no buybacks while AGEN is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
2.13%
Slight or no buyback while AGEN is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
32.67%
OCF growth at 75-90% of AGEN's 38.06%. Bill Ackman would demand better working capital management or cost discipline.
32.86%
FCF growth 50-75% of AGEN's 48.71%. Martin Whitman would see if structural disadvantages exist in generating free cash.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
83.05%
10Y OCF/share CAGR above 1.5x AGEN's 30.43%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
75.83%
5Y OCF/share CAGR 1.25-1.5x AGEN's 63.13%. Bruce Berkowitz would see if capital spending or working-capital efficiencies explain the difference.
20.41%
3Y OCF/share CAGR under 50% of AGEN's 42.69%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
95.17%
Net income/share CAGR above 1.5x AGEN's 23.51% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
79.59%
5Y net income/share CAGR 1.25-1.5x AGEN's 68.32%. Bruce Berkowitz would check if a better product mix or cost discipline explains the gap.
2.82%
Below 50% of AGEN's 37.86%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
170.99%
Positive growth while AGEN is negative. John Neff might see a strong advantage in steadily compounding net worth over a decade.
-42.91%
Negative 5Y equity/share growth while AGEN is at 69.62%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-60.55%
Negative 3Y equity/share growth while AGEN is at 60.26%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative near-term dividend growth while AGEN invests at 0.00%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.43%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-18.27%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-4.43%
We’re deleveraging while AGEN stands at 293.44%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-31.86%
Our R&D shrinks while AGEN invests at 1854.39%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-15.50%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.